STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (34,674,646)	$ (27,366,265)	$ (9,170,947)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	206,750	231,752	364,124
Amortization of debt premium	(20,819)	0	0
Issuance of common stock, warrants and options for services	565,915	694,955	454,855
Modification of warrants issued to consultants	0	76,991	0
Equity based compensation	5,105,827	3,958,637	2,636,905
Common stock contributed to 401(k) plan	165,646	155,434	158,856
Impairment loss on abandonment of patents	0	1,182	22,628
Loss on retired equipment	313	268	4,350
Gain on derivative instruments	(282,616)	(248,767)	(10,750,666)
Loss on debt extinguishment	641,276	0	0
(Increase)/decrease in assets:
Receivables	(5,394)	(7,557)	84,351
Deferred rent	745,673	769,159	544,028
Prepaid expenses	(68,268)	(158,088)	529,738
Inventory used for R&D and manufacturing	50,181	(435,392)	367,856
Deposits	150,000	(200,000)	(400,000)
Increase/(decrease) in liabilities:
Accounts payable	3,981,886	(751,971)	1,316,964
Accrued expenses	(458,633)	433,712	101,995
Deferred revenue	48	46	45
Due to employees	57,170	(78,376)	186,446
Deferred rent liability	6,358	(3,739)	(108)
Net cash used in operating activities	(23,833,333)	(22,928,019)	(13,548,580)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of equipment	(73,399)	(103,977)	(102,033)
Expenditures for patent costs	(20,132)	(34,887)	(30,728)
Net cash used in investing activities	(93,531)	(138,864)	(132,761)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants	21,148,378	28,428,641	9,788,769
Proceeds from exercise of warrants	0	3,118,387	0
Payments on obligations under capital lease	(8,452)	(8,137)	(6,858)
Net cash provided by financing activities	21,139,926	31,538,891	9,781,911
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	(2,786,938)	8,472,008	(3,899,430)
CASH AND CASH EQUIVALENTS, BEGINNING OF YEAR	8,513,620	41,612	3,941,042
CASH AND CASH EQUIVALENTS, END OF YEAR	5,726,682	8,513,620	41,612
ACCOUNTS PAYABLE
(Decrease) Increase in research and office equipment	(2,345)	(1,074)	36,622
Decrease (increase) in capital lease obligation	43	3,477	(35,995)
(Decrease) increase in patent costs	(11,685)	4,474	14,024
Decrease (increase) in accounts payable	13,987	(6,877)	(14,651)
Total	0	0	0
ADDITIONAL PAID IN CAPITAL
(Increase) in derivative liabilities	(8,463,957)	(5,320,989)	(4,200,000)
Decrease (Increase) in common stock	1,000	(16,375)	0
Increase in prepaid services	3,861	31,085	57,553
Increase in patent costs	0	9,999	0
Decrease in additional paid in capital	8,459,096	5,296,280	4,142,447
Total	0	0	0
SUPPLEMENTAL DISCLOSURE OF CASH FLOWS INFORMATION:
Cash expenditure for interest expense	$ 147,166	$ 180,654	$ 156,225